Liu K, et al. - Researchers assessed the effectiveness and safety of intravitreal injections of 0.5 mg conbercept, a new anti-VEGF drug, for treatment of age-related macular degeneration (AMD) on a schedule more manageable for patients. For treatment of AMD, an efficacy of a conbercept dosing regimen of three initial monthly administrations followed by quarterly treatments is noted. In previous reports, experts noted an inability of other anti-VEGF agents to maintain similar clinlcal benefits with the same regimen.